EMA Authorised: DuoResp Spiromax (Budesonide;formoterol fumarate dihydrate) — Teva Pharma B.V.

View source ↗

Summary

The European Medicines Agency authorised DuoResp Spiromax, a budesonide/formoterol inhaler, for the treatment of chronic obstructive pulmonary disease and asthm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• DuoResp Spiromax (budesonide/formoterol fumarate dihydrate)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive;Asthma. MAH: Teva Pharma B.V.. Decision date: 08/07/2024